Renalytix Plc (LON:RENX – Get Free Report)’s stock price rose 10% during trading on Monday . The company traded as high as GBX 4.50 and last traded at GBX 4.11. Approximately 928,051 shares were traded during trading, an increase of 1% from the average daily volume of 917,086 shares. The stock had previously closed at GBX 3.73.
Renalytix Stock Performance
The stock’s 50 day moving average is GBX 2.84 and its two-hundred day moving average is GBX 2.68. The stock has a market capitalization of £17.96 million, a price-to-earnings ratio of -1.03 and a beta of 1.81. The company has a current ratio of 1.57, a quick ratio of 2.42 and a debt-to-equity ratio of -483.33.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Stories
- Five stocks we like better than Renalytix
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
